Search
Sunday 31 January 2016
  • :
  • :

3 Stocks Tumbled – Lennar Corporation (NYSE:LEN), Gilead Sciences, Inc (NASDAQ:GILD), Mosaic Co (NYSE:MOS)

On Monday, Lennar Corporation (NYSE:LEN)’s shares dropped -0.64% to $48.23.

On April 8, Lennar Corporation (LEN), declared that its Board of Directors has declared a quarterly cash dividend of $0.04 per share for both Class A and Class B common stock payable on May 6, 2015 to holders of record at the close of business on April 22, 2015.

Lennar Corporation, together with its auxiliaries, engages in the homebuilding activities in the United States. The company operates through Homebuilding East, Homebuilding Central, Homebuilding West, Homebuilding Southeast Florida, Homebuilding Houston, Financial Services, Rialto, and Lennar Multifamily segments. Its homebuilding activities primarily comprise the construction and sale of single-family attached and detached homes to first-time, move-up, and active adult homebuyers, in addition to the purchase, development, and sale of residential land.

At the end of Monday’s trade, Gilead Sciences, Inc (NASDAQ:GILD)‘s shares dipped -0.72% to $100.65.

On April 7, Gilead Sciences, Inc (GILD), declared that it has presented a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.

TAF is a novel nucleotide reverse transcriptase inhibitor (NRTI) that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF), in addition to improved renal and bone laboratory parameters as contrast to TDF in clinical trials.

“Gilead has a long history of innovating HIV treatments, and with F/TAF we have the potential to further optimize therapies for HIV patients who face a lifetime of antiretroviral treatment,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “With its high antiviral efficacy and favorable safety profile, F/TAF may offer an improved backbone for a new generation of HIV regimens.”

The F/TAF NDA is supported by data from Phase 3 clinical studies evaluating the safety and efficacy of E/C/F/TAF for the treatment of HIV-1 infection among treatment-naïve adults, in which the F/TAF-based regimen (administered as E/C/F/TAF) resulted in non-inferior efficacy and improved renal and bone laboratory parameters as contrast to F/TDF-based therapy (administered as E/C/F/TDF or Stribild®). The NDA is also supported by data from additional Phase 3 studies evaluating the F/TAF-based regimen (administered as E/C/F/TAF) among treatment-naïve adolescents, virologically suppressed adults who switched regimens and adults with mild-to-moderate renal impairment. Lastly, bioequivalence studies demonstrated that the formulation of the fixed-dose combinations of F/TAF achieved the same drug levels in the blood as in E/C/F/TAF.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.

Mosaic Co (NYSE:MOS), ended its Monday’s trading session with -0.71% loss, and closed at $45.00.

On April 15, Mosaic Co (MOS), release 2015 first quarter earnings results on Thursday, April 30, 2015, before the market opening of the New York Stock Exchange.

Mosaic anticipates to release earnings results at about 7:00 a.m. Eastern Daylight Time, simultaneously posting performance data on its website in a tabular form. Historical performance data for Mosaic’s past eight quarters is presently accessible at www.mosaicco.com/investor/financialdata.

The Company will host a conference call to talk about the results on April 30, 2015, starting at 9:00 a.m. Eastern Daylight Time. A webcast of the conference call counting the presentation slides can be accessed by visiting Mosaic’s website. An audio replay of the call will be accessible up to one year from the time of the earnings call.

In addition, Mosaic will hold its 2015 Annual Meeting of Stockholders on Thursday, May 14, 2015, at 11:00 a.m. Eastern Daylight Time (10:00 a.m. Central Daylight Time).

The Mosaic Company produces and markets concentrated phosphate and potash crop nutrients for the agricultural industry worldwide. It operates through two segments, Phosphates and Potash. The Phosphates segment owns and operates mines in Florida. It offers concentrated phosphate crop nutrients, such as diammonium phosphate, monoammonium phosphate, and ammoniated phosphate products.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.